Champions Oncology Inc (NASDAQ: CSBR) has reported earnings for its third fiscal quarter (ending January 31) of $0.33 versus a loss $-0.19 for the same period a year ago. This result exceeded the consensus estimate of $-0.01 by $0.34. For the latest four quarters through January 31, E.P.S. were $0.47 versus $-0.72 for the same period a year ago.
Recent Price Action
Champions Oncology Inc (NASDAQ: CSBR) stock enjoyed a significant increase of 10.0% on 3/11/25. The stock closed at $9.79. Moreover, above average trading volume at 134% of normal accompanied the advance. The stock has been exceptionally strong relative to the market over the last nine months but has declined -5.8% during the last week.
Current PriceTarget Research Rating
Champions Oncology is currently unrated.
Rating Review
The stock is currently unrated.
Be the first to comment